ClinicalTrials.gg
RecruitingNCT06880835INHALE-AIDExUpdated Jul 16, 2026

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

An interventional study of Control IQ + sleep or exercise activity with TI in Diabetes Mellitus, Type 1, sponsored by Jaeb Center for Health Research. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Jaeb Center for Health Research · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research — 1 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Jaeb Center for Health Research.

Planned enrollment
23rd of 29
30 · median 74
Started
2025
with 1 other
No phase
10 of 36
1 open now
Registered
35th of 36
by date

Among the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, this one is the 23rd largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 35th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, or all of them as a file.
02

Study summary

This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology ("Control-IQ" which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to complete three study exercise visits in the clinic.

Read the detailed description

The study is a 3-period randomized crossover trial, each with a structured afternoon exercise session following a standard lunch meal.

9 participants completed Phase 1 sessions which included (1) TI for meal bolus with pump in sleep mode, (2) RAA for meal bolus with pump in sleep mode, and (3) RAA for meal bolus with pump in standard mode with transition to exercise mode one hour before start of exercise.

21 participants will complete the Phase 2 sessions which will include: (1) TI for meal bolus with pump in exercies mode, (2) TI for meal air bolus (i.e., the infusion set is disconnected from the pump and the TI bolus and carbohydrates are reported in the system but no pump insulin is administered) with pump in exercise mode, and (3) RAA for meal bolus with pump in exercise mode.

The study is being done to compare the efficacy and safety of TI versus RAA given as bolus for meal prior to initiating aerobic exercise in adults ≥18 to ≤ 65 years of age with T1D using Control-IQ.

All participants will complete 3 exercise sessions, with the order determined through randomization. Participants who complete Phase 1 may also participate in Phase 2 if they choose to.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • Diabetes Mellitus, Type 1
  • Exercise
  • Technosphere Insulin
  • Automated Insulin Delivery
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to provide for study participation
  2. Age ≥18 years to 65 years
  3. Clinical diagnosis of T1D (per the Investigator)
  4. Using Tandem t:slim X2 or Tandem Mobi insulin pump with Control-IQ for at least 90 days prior to screening visit
  5. Using insulin aspart or insulin lispro in Tandem insulin pump
  6. Total daily insulin dose 20 to 80 units
  7. Usual RAA insulin bolus for 50 gram carbohydrate lunch meal is ≤12 units
  8. Physically active, with at least 3 moderate or vigorous exercise sessions ≥30 minutes per typical week self-reported by participant
  9. No medical, psychiatric, or other conditions, or medications being taken that in the Investigator's judgement would be a safety concern for participation in the study
  10. No (ECG) abnormality that in the judgment of the investigator, which will take into consideration the usual exercise performed by the participant and their overall medical condition, increases the risk of exercise
  11. Investigator believes that the participant can safely follow the protocol
  12. Able to read and understand written and spoken English or Spanish

Exclusion criteria

Exclusion Criteria:

  1. Use of inhaled insulin within one week prior to screening visit
  2. History of asthma, (COPD), or any other pulmonary disease (e.g., cystic fibrosis or bronchopulmonary dysplasia), or significant congenital or acquired cardiopulmonary disease as judged by the Investigator
  3. Smoking (includes cigarettes, cigars, pipes, marijuana, and vaping devices) within 90 days prior to screening visit and no plans to smoke during the study
  4. History or current diagnosis of lung cancer
  5. (FEV1) measurement of \<70% of predicted Global Lung Function Initiative value
  6. Pregnant or lactating, planning to become pregnant during the study, or is of and not on acceptable form of (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months )

    • A pregnancy test is required for any person of childbearing potential.
  7. An event of severe hypoglycemia, as judged by the Investigator, within the 90 days prior to screening visit
  8. An episode of diabetic ketoacidosis (DKA) as defined in section 5.2 within the 90 days prior to screening visit
  9. Any disease other than diabetes or current use (or anticipated use during the study) of any medication (e.g., beta blocker) that, in the judgment of the Investigator, may substantially impact glucose metabolism
  10. Use of a non-insulin glucose-lowering medication (or weight-reduction medication with glucose-lowering effect) within 4 weeks prior to screening visit
  11. Exposure to any drug in the 90 days prior to the screening visit
  12. Current or anticipated acute uses of oral, inhaled, or injectable during the time period of the study (topical or intranasal glucocorticoid use is acceptable)
  13. Current use of Hydroxyurea medication
  14. Current or anticipated use of a low carbohydrate diet (\<50 grams/day) or low calorie diet (\<800 kcal/day) during the time period of the study
  15. Current treatment for diabetic retinopathy
  16. Known stage 4/5 chronic kidney disease or on dialysis
  17. Having a direct supervisor at place of employment who is directly involved in conducting the clinical trial (as a study Investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Control IQ + sleep or exercise activity with TI

    PHASE 1: TI for meal bolus with Control IQ + sleep activity pump setting. PHASE 2: TI for meal bolus with Control IQ+ exercise activity pump setting.

    Device: Control IQ + sleep or exercise activity with TI

  • No intervention
    Control IQ + sleep or exercise activity with Rapid-Acting Analogue (RAA) Comparator

    PHASE 1: RAA for meal bolus with the Control IQ + sleep activity pump setting. PHASE 2: RAA for meal bolus with Control IQ + exercise activity pump setting.

  • No intervention
    Control IQ + exercise activity with Rapid-Acting Analogue (RAA) or TI air bolus Control

    PHASE 1: RAA for meal bolus with Control IQ pump setting with transition to Control IQ + exercise activity pump setting one hour before start of exercise. PHASE 2: TI for meal air bolus where the infusion set is disconnected and the bolus is entered into the pump with meal carbohydrates (no subcutaneous insulin is delivered from the pump), with Control IQ + exercise activity pump setting

Interventions

  • DeviceControl IQ + sleep or exercise activity with TI

    PHASE 1: TI for meal bolus with Control IQ + sleep activity pump setting PHASE 2: TI for meal bolus with Control IQ + exercise activity pump setting

06

What researchers measure

Primary outcomes

  1. PHASE 1: Blood glucose <70 mg/dL

    Blood glucose \<70 mg/dL within 90 minutes from the start of exercise

    Time frame: 90 minutes

  2. PHASE 2: Blood glucose <70 mg/dL

    Blood glucose \<70 mg/dL within 90 minutes from the start of exercise

    Time frame: 90 minutes

Other outcomes

  1. PHASE 1: Exploratory Efficacy Outcome: Change in blood glucose from exercise start to nadir glucose

    Change in blood glucose from exercise start to nadir glucose within 90 minutes from start of exercise

    Time frame: 90 minutes

  2. PHASE 1: Exploratory Efficacy Outcome: Change in CGM glucose from exercise start to nadir glucose

    Change in CGM glucose from exercise start to nadir glucose within 90 minutes from start of exercise

    Time frame: 90 minutes

  3. PHASE 1: Exploratory Efficacy Outcome: Time in range 70-180 mg/dL

    Time in range 70-180 mg/dL within 90 minutes from start of exercise

    Time frame: 90 minutes

  4. PHASE 1: Exploratory Efficacy Outcome: Time in tight range 70-140 mg/dL

    Time in tight range 70-140 mg/dL within 90 minutes from start of exercise

    Time frame: 90 minutes

  5. PHASE 1: Exploratory Efficacy Outcome: Mean glucose

    Mean glucose within 90 minutes from start of exercise

    Time frame: 90 minutes

  6. PHASE 1: Exploratory Efficacy Outcome: CGM glucose <54 mg/dL

    CGM glucose \<54 mg/dL within 90 minutes from start of exercise

    Time frame: 90 minutes

  7. PHASE 1: Exploratory Efficacy Outcome: CGM glucose <70 mg/dL

    CGM glucose \<70 mg/dL within 90 minutes from start of exercise

    Time frame: 90 minutes

  8. PHASE 1: Exploratory Efficacy Outcome: CGM glucose >250 mg/dL

    CGM glucose \>250 mg/dL within 90 minutes from start of exercise

    Time frame: 90 minutes

  9. PHASE 1: Exploratory Efficacy Outcome: CGM glucose >300 mg/dL

    CGM glucose \>300 mg/dL within 90 minutes from start of exercise

    Time frame: 90 minutes

  10. PHASE 1: Safety Outcome: Severe hypoglycemia events

    Defined as events requiring assistance of another person due to cognitive impairment to actively administer carbohydrate, glucagon, or other resuscitative actions

    Time frame: From enrollment to last clinic visit (up to ~12 weeks)

  11. PHASE 1: Safety Outcome: Blood glucose <54 mg/dL during clinic

    Blood glucose \<54 mg/dL between start of meal and discharge from clinic

    Time frame: 210 minutes

  12. PHASE 1: Safety Outcome: Blood glucose <70 mg/dL during clinic

    Blood glucose \<70 mg/dL between start of meal and discharge from clinic

    Time frame: 210 minutes

  13. PHASE 1: Safety Outcome: Adverse events related to exercise procedure

    Adverse events related to the exercise procedure

    Time frame: From enrollment to last clinic visit (up to ~12 weeks)

  14. PHASE 1: Safety Outcome: Adverse events associated with technosphere insulin inhalation

    Adverse events associated with technosphere insulin (TI) inhalation: hypersensitivity reaction, acute bronchospasm, treatment provided for asthma symptoms, or other symptoms associated with TI dosing

    Time frame: From enrollment to last clinic visit (up to ~12 weeks)

  15. PHASE 2: Exploratory Efficacy Outcome: Change in blood glucose from exercise start to nadir glucose

    Change in blood glucose from exercise start to nadir glucose within 90 minutes from start of exercise

    Time frame: 90 minutes

  16. PHASE 2: Exploratory Efficacy Outcome: Change in CGM glucose from exercise start to nadir glucose

    Change in CGM glucose from exercise start to nadir glucose within 90 minutes from start of exercise

    Time frame: 90 minutes

  17. PHASE 2: Exploratory Efficacy Outcome: Time in range 70-180 mg/dL

    Time in range 70-180 mg/dL within 90 minutes from start of exercise

    Time frame: 90 minutes

  18. PHASE 2: Exploratory Efficacy Outcome: Time in tight range 70-140 mg/dL

    Time in tight range 70-140 mg/dL within 90 minutes from start of exercise

    Time frame: 90 minutes

  19. PHASE 2: Exploratory Efficacy Outcome: Mean glucose

    Mean glucose within 90 minutes from start of exercise

    Time frame: 90 minutes

  20. PHASE 2: Exploratory Efficacy Outcome: CGM glucose <54 mg/dL

    CGM glucose \<54 mg/dL within 90 minutes from start of exercise

    Time frame: 90 minutes

  21. PHASE 2: Exploratory Efficacy Outcome: CGM glucose <70 mg/dL

    CGM glucose \<70 mg/dL within 90 minutes from start of exercise

    Time frame: 90 minutes

  22. PHASE 2: Exploratory Efficacy Outcome: CGM glucose >250 mg/dL

    CGM glucose \>250 mg/dL within 90 minutes from start of exercise

    Time frame: 90 minutes

  23. PHASE 2: Exploratory Efficacy Outcome: CGM glucose >300 mg/dL

    CGM glucose \>300 mg/dL within 90 minutes from start of exercise

    Time frame: 90 minutes

  24. PHASE 2: Safety Outcome: Severe hypoglycemia events

    Defined as events requiring assistance of another person due to cognitive impairment to actively administer carbohydrate, glucagon, or other resuscitative actions

    Time frame: From enrollment to last clinic visit (up to ~12 weeks)

  25. PHASE 2: Safety Outcome: Blood glucose <54 mg/dL during clinic

    Blood glucose \<54 mg/dL between start of meal and discharge from clinic

    Time frame: 210 minutes

  26. PHASE 2: Safety Outcome: Blood glucose <70 mg/dL during clinic

    Blood glucose \<70 mg/dL between start of meal and discharge from clinic

    Time frame: 210 minutes

  27. PHASE 2: Safety Outcome: Adverse events related to exercise procedure

    Adverse events related to the exercise procedure

    Time frame: From enrollment to last clinic visit (up to ~12 weeks)

  28. PHASE 2: Safety Outcome: Adverse events associated with technosphere insulin inhalation

    Adverse events associated with technosphere insulin (TI) inhalation: hypersensitivity reaction, acute bronchospasm, treatment provided for asthma symptoms, or other symptoms associated with TI dosing

    Time frame: From enrollment to last clinic visit (up to ~12 weeks)

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — A limited dataset is expected to be made available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 16 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 18, 2025
StartActual
Jun 5, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06880835
Collaborators
Mannkind Corporation, Tandem Diabetes Care, Inc., The Leona M. and Harry B. Helmsley Charitable Trust
Responsible party
Sponsor
First posted
Mar 18, 2025
Start date
Jun 5, 2025
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 16, 2026

Study contacts

Robin Gal, MSPH
Contact
rgal@jaeb.org
813-975-8690
Michael R Rickels, MD, MA
principal investigator · University of Pennsylvania
Michael Ridell, PhD
study chair · York University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion